Evogene Ltd. has announced its financial results for the first quarter ended March 31, 2025. The company reported total revenues of approximately $2.4 million for the quarter, down from approximately $4.2 million in the same period of 2024. This decline was attributed to the absence of significant license fee payments that were present in 2024, specifically from Lavie Bio's collaboration with Corteva and AgPlenus's collaboration with Bayer. In 2025, revenue was primarily driven by an increase in seed sales by Casterra. The operating loss for the first quarter of 2025 was approximately $4.1 million, consistent with the operating loss reported in the first quarter of 2024. Net financing income saw a significant increase to approximately $1.1 million, compared to approximately $241 thousand in the same period last year, due to accounting treatment of pre-funded warrants and warrants issued in Evogene's August 2024 fundraising. The net loss for the first quarter of 2025 was approximately $3.0 million, showing an improvement from the $3.8 million net loss reported in the first quarter of 2024. This reduction in net loss was primarily due to decreased operating expenses and increased net financing income, partially offset by decreased revenues. As of March 31, 2025, Evogene held consolidated cash, cash equivalents, and short-term bank deposits totaling approximately $9.8 million, compared to approximately $15.3 million as of December 31, 2024. This figure does not include approximately $2.0 million due from Casterra's outstanding customers, which was mostly received in the second quarter of 2025. Additionally, the company is anticipating proceeds from the sale of Lavie Bio's assets and the MicroBoost AI for Ag tech-engine to ICL, with the transaction expected to close in the second quarter of 2025, subject to customary closing conditions.